Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor
申请人:Drescher Karla
公开号:US20090012074A1
公开(公告)日:2009-01-08
The present invention relates to aromatic compounds of the formula I
wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R
a
and wherein Ar may also carry 1 or 2 radicals R
b
;
X is N or CH;
Y is O, S, —CH═N—, —CH═CH— or —N═CH—;
A is CH
2
, O or S;
E is CR
6
R
7
or NR
3
;
R
1
is C
1
-C
4
-alkyl, C
3
-C
4
-cycloalkyl, C
3
-C
4
-cycloalkylmethyl, C
3
-C
4
-alkenyl, fluorinated C
1
-C
4
-alkyl, fluorinated C
3
-C
4
-cycloalkyl, fluorinated C
3
-C
4
-cycloalkylmethyl, fluorinated C
3
-C
4
-alkenyl, formyl or C
1
-C
3
-alkylcarbonyl;
R
1a
is H, C
2
-C
4
-alkyl, C
3
-C
4
-cycloalkyl, C
3
-C
4
-alkenyl, fluorinated C
1
-C
4
-alkyl, fluorinated C
3
-C
4
-cycloalkyl, or R
1a
and R
2
together are (CH
2
)
n
with n being 2 or 3, or R
1a
and R
2a
together are (CH
2
)
n
with n being 2 or 3;
R
2
and R
2a
are independently of each other H, CH
3
, CH
2
F, CHF
2
or CF
3
;
R
3
is H or C
1
-C
4
-alkyl;
R
6
, R
7
independently of each other are selected from H, C
1
-C
2
-alkyl and fluorinated C
1
-C
2
-alkyl;
and the physiologically tolerated acid addition salts thereof.
The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
本发明涉及公式I的芳香族化合物,其中Ar是苯基或含有5或6个成员的芳香族C-连接杂环基团,其中Ar可以携带1个基团Ra,也可以携带1或2个基团Rb;X是N或CH;Y是O,S,-CH═N-,-CH═CH-或-N═CH-;A是CH2,O或S;E是CR6R7或NR3;R1是C1-C4烷基,C3-C4环烷基,C3-C4环烷基甲基,C3-C4烯基,氟代C1-C4烷基,氟代C3-C4环烷基,氟代C3-C4环烷基甲基,氟代C3-C4烯基,甲酰基或C1-C3烷基羰基;R1a是H,C2-C4烷基,C3-C4环烷基,C3-C4烯基,氟代C1-C4烷基,氟代C3-C4环烷基,或R1a和R2一起是(CH2)n,其中n为2或3,或R1a和R2a一起是(CH2)n,其中n为2或3;R2和R2a相互独立地是H,CH3,CH2F,CHF2或CF3;R3是H或C1-C4烷基;R6,R7相互独立地选择自H,C1-C2烷基和氟代C1-C2烷基;以及其生理耐受酸盐。本发明还涉及使用公式I的化合物或其药学上可接受的盐制备用于治疗可通过多巴胺D3受体配体治疗的医疗障碍的制药组合物的用途。